tiprankstipranks
Immuron Limited (AU:IMC)
:IMC
Australian Market
Holding AU:IMC?
Track your performance easily

Immuron Limited (IMC) Share Price & Analysis

2 Followers

IMC Stock Chart & Stats


Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.27%99.73%
― Other Institutional Investors
99.73% Public Companies and
Individual Investors

IMC FAQ

What was Immuron Limited’s price range in the past 12 months?
Immuron Limited lowest share price was AU$0.07 and its highest was AU$0.17 in the past 12 months.
    What is Immuron Limited’s market cap?
    Immuron Limited’s market cap is AU$18.10M.
      When is Immuron Limited’s upcoming earnings report date?
      Immuron Limited’s upcoming earnings report date is Feb 26, 2025 which is in 47 days.
        How were Immuron Limited’s earnings last quarter?
        Currently, no data Available
        Is Immuron Limited overvalued?
        According to Wall Street analysts Immuron Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Immuron Limited pay dividends?
          Immuron Limited does not currently pay dividends.
          What is Immuron Limited’s EPS estimate?
          Immuron Limited’s EPS estimate is 0.
            How many shares outstanding does Immuron Limited have?
            Immuron Limited has 229,145,430 shares outstanding.
              What happened to Immuron Limited’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of Immuron Limited?
              Currently, no hedge funds are holding shares in AU:IMC
              ---

              Immuron Limited Stock Smart Score

              Company Description

              Immuron Limited

              Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
              ---
              Popular Stocks
              ---
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis